Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein

Immunol Cell Biol. 2004 Oct;82(5):523-30. doi: 10.1111/j.0818-9641.2004.01283.x.

Abstract

In the present study we investigated the immunomodulatory effects of two adjuvants, liposomal lipid A [L(LA)] and CpG-containing oligodeoxynucleotides (CpG ODN), to the HIV-1 ogp140 envelope protein. Administration of each of these adjuvants separately with unencapsulated ogp140 resulted in low antibody titres. Encapsulation of ogp140 in liposomes containing lipid A resulted in a sixfold increase in anti-ogp140 antibodies. The antibody titres were further enhanced threefold by the addition of CpG ODN. Priming and boosting BALB/c mice with unencapsulated ogp140 with L(LA) or encapsulation in liposomes containing lipid A induced a mixed Th1/Th2 type of immune response. In contrast, immunization with L(ogp140 + LA) plus CpG ODN switched the immune response to a Th-1 response with elevated anti-ogp140 IgG2a antibodies and IFN-gamma levels. Both adjuvants induced excellent ogp140-specific proliferative and CTL responses. Therefore, for the induction of high titre antibodies, but not for cellular responses, the antigen and lipid A have to be present in the same liposomes. These results can have significant implications in directing the Th1 or Th2 differentiation of antigen-specific immune responses in the context of vaccine development.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antibody Formation / drug effects
  • CpG Islands / immunology*
  • Dimerization
  • Female
  • Gene Products, env / immunology*
  • HIV-1 / chemistry
  • HIV-1 / immunology*
  • Lipid A / administration & dosage
  • Lipid A / pharmacology
  • Liposomes / administration & dosage
  • Liposomes / pharmacology
  • Mice
  • Mice, Inbred BALB C
  • Oligodeoxyribonucleotides / administration & dosage
  • Oligodeoxyribonucleotides / pharmacology
  • T-Lymphocytes, Cytotoxic / immunology*
  • Th1 Cells / drug effects
  • Th2 Cells / drug effects
  • env Gene Products, Human Immunodeficiency Virus

Substances

  • Adjuvants, Immunologic
  • Gene Products, env
  • Lipid A
  • Liposomes
  • Oligodeoxyribonucleotides
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1